Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valsartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 13/20 | 0.72 |
| ▸ | LTB4R2 | Q9NPC1 | 9/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valsartan SCHEMBL2542 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL2329 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL29406387 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL157179 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL1560689 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21408288 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21408289 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21121526 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21121527 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL20527991 | 0.99 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-111053910-A | Composition comprising fatty acid or derivative thereof and disubstituted biphenyl derivative | 黄泳华 | 2020-04-24 | — | — | CN | claimed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | claimed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | claimed |
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210361610-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2021-11-25 | — | — | US | disclosed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| EP-3685833-A1 | COMPOUND COMPRISING AN ARB AND A NEPI | Novartis AG (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-2340828-B1 | PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND A NEP INHIBITOR | NOVARTIS AG (CH) | 2020-07-15 | — | — | EP | disclosed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | disclosed |
| CN-111053910-A | Composition comprising fatty acid or derivative thereof and disubstituted biphenyl derivative | 黄泳华 | 2020-04-24 | — | — | CN | disclosed |
| US-20090156585-A1 | ORGANIC COMPOUNDS | NOVARTIS PHARMACEUTICALS CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | disclosed |
| WO-2007056546-A1 | PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR | NOVARTIS AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361610-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | AGTR1 4/4885LTB4R2 1393/4885ABCB11 1638/4885 |
| US-11642329-B2 | Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations | MME, DNPEP, AGTR1 | AGTR1 3/4885LTB4R2 2312/4885ABCB11 1883/4885 |
| US-20090156585-A1 | ORGANIC COMPOUNDS | REN, AGTR1, AGTR2 | AGTR1 2/4885LTB4R2 310/4885ABCB11 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.